Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Candel Therapeutics公布了来自SITC的Enlighten发现平台的临床前数据;第一种实验药物是Alpha-201-Macro1,这是一种旨在激活先天免疫监测的在研病毒免疫疗法
Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Candel Therapeutics公布了来自SITC的Enlighten发现平台的临床前数据;第一种实验药物是Alpha-201-Macro1,这是一种旨在激活先天免疫监测的在研病毒免疫疗法